Testing an automated insulin pump in adults with poorly controlled type 1 diabetes
Tests an automated insulin pump in adults with type 1 diabetes and high blood sugar.
Plain-language title generated from the registry record
Registry title: Starting Technology in At Risk Type 1 Diabetes Study
Key facts
- Where
- Santa Monica, Sylmar, and Torrance, United StatesSee the 3 sites
Where in United States
- UCLASanta Monica, United StatesTaking people
- Olive View-UCLA Medical CenterSylmar, United StatesTaking people
- Harbor-UCLA Medical CenterTorrance, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of California, Los Angeles
- Trial code
- NCT06453928
- Record updated
- 29 October 2026
- Original description
Diabetes technology has revolutionized T1D management, disparities in technology access are evident among racial-ethnic minorities, patients with lower socioeconomic status and those with poorly controlled T1D (A1c>8.5%). In order to examine whether diabetes technology can reduce diabetes care burdens and enhance outcomes among some of highest need patients, diabetes technology clinical trials must be expanded beyond the very select populations included in studies thus far (ie., mostly White, higher SES). Therefore, the investigators propose to perform a pilot RCT of hybrid closed-loop insulin pump therapy (HCL) in 40 diverse adult patients with poorly controlled T1D (HbA1c ≥8.0%) from the largest academic and safety net health systems in the Los Angeles region to determine the feasibility of a RCT in this population and identify facilitators and barriers of effective use of closed loop insulin pump therapy in patients with poorly controlled T1D.Read full original descriptionShow less
Starting Technology in At Risk Type 1 Diabetes (STAR-T1D) Study
Diabetes technology has revolutionized T1D management, disparities in technology access are evident among racial-ethnic minorities, patients with lower socioeconomic status and those with poorly controlled T1D (A1c>8.5%). In order to examine whether diabetes technology can reduce diabetes care burdens and enhance outcomes among some of highest need patients, diabetes technology clinical trials must be expanded beyond the very select populations included in studies thus far (ie., mostly White, higher SES). Therefore, the investigators propose to perform a pilot RCT of hybrid closed-loop insulin pump therapy (HCL) in 40 diverse adult patients with poorly controlled T1D (HbA1c ≥8.0%) from the largest academic and safety net health systems in the Los Angeles region to determine the feasibility of a RCT in this population and identify facilitators and barriers of effective use of closed loop insulin pump therapy in patients with poorly controlled T1D.
Inclusion: Type 1 Diabetes; A1c ≥ 8.0%; Not insulin pump user; Primary language of English or Spanish; Have medical insurance coverage.
Exclusion: Have cognitive, physical or mental impairment precluding diabetes technology use; Have comorbidities that can result in inaccurate hemoglobin A1c; No measured A1c in the past year; Limited life expectancy (<1 year); Pregnancy.